Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a 6 mg subcutaneous injection for rapid relief of acute migraine attacks, with or without aura, in adult patients. It is approved throughout the European Union for this indication and belongs to the acute migraine treatment class.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing of this EU‑approved injectable migraine therapy. The company ensures quality control, regulatory compliance and timely delivery to meet the needs of healthcare providers across multiple regions.

Imigran (sumatriptan) is indicated for the acute treatment of migraine, a neurovascular headache disorder.

- Migraine with aura: provides rapid relief of headache pain, photophobia, phonophobia and nausea associated with attacks. - Migraine without aura: reduces the intensity and duration of headache and associated symptoms when taken early in an attack. - Acute episodic migraine: offers a fast‑acting option for patients needing subcutaneous administration for quick onset of effect.

Sumatriptan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Chest discomfort or tightness - Flushing or warmth - Tingling or numbness of fingers or toes - Nausea or abdominal pain

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain or myocardial infarction - Serotonin syndrome when combined with other serotonergic agents - Anaphylactic or severe allergic reactions

Before prescribing Imigran, clinicians should consider several safety precautions.

- Assess cardiovascular risk: evaluate history of heart disease before use. - Avoid in uncontrolled hypertension: do not administer if blood pressure is not well controlled. - Caution with ischemic heart disease: patients with prior coronary events should be evaluated carefully. - Do not combine with MAO inhibitors: avoid use within 14 days of MAOI therapy. - Pregnancy category C: discuss potential risks with pregnant or planning‑pregnant patients. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Sumatriptan can interact with several drug classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate severe hypertension. - Ergotamine derivatives: combined vasoconstriction can increase risk of coronary events. - Other triptans: additive vasoconstrictive effect may be hazardous. - Serotonergic agents (SSRIs, SNRIs, triptans): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels. - Beta‑blockers: may enhance hypotensive effects. - Oral contraceptives: can raise sumatriptan concentrations. - Alcohol: may exacerbate dizziness or flushing.